Intelligent Bio 2025 Q3 Earnings Narrowed Losses with Net Income Improving by 14.6%

Intelligent Bio (INBS) reported its fiscal 2025 Q3 earnings on May 13th, 2025. Intelligent Bio experienced a 0.6% decrease in total revenue to $902,138 for Q3 2025, compared to $907,642 in Q3 2024. The company reported a narrowed net loss of $2.55 million for the quarter, improving by 14.6% compared to the Q3 2024 loss of $2.99 million. Intelligent Bio's results indicate ongoing financial challenges but also reflect improvements in operational efficiency and a strategic focus on higher-margin products, aligning with their guidance expectations.

Revenue
Intelligent Bio's revenue for Q3 2025 was impacted by a 0.6% decrease in overall sales, totaling $902,138 compared to $907,642 in Q3 2024. Within this, cartridge sales contributed $442,029, showcasing their significance in the company's revenue structure. Reader sales followed with $165,801, while other sales added $121,037, bringing the total segment revenue to $728,867.

Earnings/Net Income
Intelligent Bio significantly improved its earnings per share, narrowing losses to $0.44 in 2025 Q3, a substantial advancement from the $1.43 loss per share in Q3 2024, marking a 69.2% improvement. The net loss narrowed to $2.55 million, indicating an ongoing reduction in losses.

Price Action
The stock price of Intelligent Bio climbed 6.25% during the latest trading day, jumped 13.33% during the most recent full trading week, and surged 11.48% month-to-date.

Post-Earnings Price Action Review
The strategy of purchasing Intelligent Bio (INBS) shares following its revenue increase on the financial report release date and holding for 30 days yielded moderate returns over the past five years, albeit with significant volatility. The compound annual growth rate (CAGR) was -17.8%, indicating a decline in portfolio value over the period. The maximum drawdown of -43.1% highlighted the strategy's high risk, especially during market downturns. However, recent revenue growth and gross profit improvements suggest potential for future performance enhancements. Investors should weigh these findings alongside other factors and prevailing market conditions before making investment decisions.

CEO Commentary
Intelligent Bio Solutions Inc. experienced robust growth in the fiscal third quarter, with a 20% increase in revenue and a 91% rise in gross profit year-over-year. President and CEO Harry Simeonidis emphasized that the ongoing expansion into safety-critical industries and the success of higher-margin cartridge sales, now constituting 58% of total sales, are key drivers of this performance. He noted a significant reduction in losses, attributing this to improved cost control and operational efficiency. The multilingual upgrades to the drug screening system enhance accessibility, supporting the company's global scalability and laying a foundation for sustainable revenue growth.

Guidance
Intelligent Bio Solutions Inc. anticipates continued growth driven by the adoption of its cartridge sales and ongoing international expansion. The company is focused on strengthening its global presence, with plans to enhance its drug screening system's multilingual capabilities to ensure widespread accessibility. The leadership expects these strategic initiatives will support sustained commercial growth and position the company favorably for broader market distribution in upcoming quarters.

Additional News
In recent developments, Intelligent Bio Solutions has expanded its distribution network in Saudi Arabia, partnering with QabasTech as its exclusive distributor, marking further growth in the region. The company also launched three new localized websites in Arabic, Italian, and Spanish, unlocking commercial access to regions representing over 1.4 billion people. This multilingual rollout aligns with product readiness and accelerates international sales pipeline development. Additionally, Intelligent Bio Solutions has strengthened its intellectual property portfolio by securing its sixth U.S. patent for the Intelligent Fingerprinting Drug Screening Cartridge, enhancing its competitive edge in the non-invasive testing market.